TransMedics Group (NASDAQ:TMDX) Receives Overweight Rating from Piper Sandler

Piper Sandler reiterated their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report sent to investors on Tuesday, Benzinga reports. Piper Sandler currently has a $180.00 price objective on the stock.

A number of other research firms have also recently weighed in on TMDX. Canaccord Genuity Group dropped their price target on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Morgan Stanley increased their price target on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Oppenheimer dropped their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. dropped their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Stock Down 29.9 %

NASDAQ:TMDX opened at $88.50 on Tuesday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $177.37. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of 94.15 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The stock’s 50 day moving average price is $146.02 and its two-hundred day moving average price is $140.16.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the company earned ($0.12) EPS. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. Equities research analysts expect that TransMedics Group will post 1.22 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,205 shares of company stock valued at $9,981,907 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the business. Fidelis Capital Partners LLC bought a new stake in shares of TransMedics Group during the 1st quarter worth $35,000. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth $47,000. USA Financial Formulas bought a new stake in shares of TransMedics Group during the 3rd quarter worth $55,000. J.Safra Asset Management Corp lifted its position in shares of TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the last quarter. Finally, Signaturefd LLC lifted its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.